GenUs BioSystems

GenUs BioSystems is a contract research organization specializing in microarray experimentation and analysis, with a focus on gene expression data optimization.

Reviewed by 7wData
Share Email

On this page

Profile

Optimizes gene expression data analysis for researchers using microarray technology.

GenUs BioSystems is a contract research organization specializing in microarray experimentation and analysis, with a focus on gene expression data optimization. Founded with a scientist-to-scientist approach, the company provides end-to-end solutions for gene expression experiments, from sample processing to data analysis. Their services include RNA isolation, amplification, microarray processing, and bioinformatics, with a claimed ability to work with samples as small as 100 picograms.

The company participated in the FDA-led MicroArray Quality Control (MAQC) Consortium, where it reportedly delivered highly reproducible results. Key personnel include Senior Intellectual Property Counsel Christopher Arnold and product leader Sean Case, who brings 16+ years in genomics and diagnostics. The company’s website emphasizes rapid turnaround times (as little as 5 days) and unlimited post-experiment consulting. No recent funding rounds or revenue figures are publicly disclosed, and the company’s online presence appears outdated, with no significant updates since the early 2020s.

Track GenUs BioSystems and 240+ vendors.

335k+ subscribers read the daily AI & data note. One email, both newsletters. Unsubscribe anytime.

Who buys this

  • Academic research labs studying genomics
  • Pharmaceutical companies developing gene-based therapies
  • Biotech firms requiring precision gene expression data
  • Clinical research organizations (CROs) outsourcing microarray work

Strengths and what to watch

Strengths

  • Specialization in handling ultra-low RNA quantities (down to 100 picograms)
  • Participation in FDA-led MAQC Consortium, indicating regulatory alignment
  • Turnaround times as fast as 5 days for time-sensitive research

Watch for

  • Dated online presence suggests limited recent activity or investment
  • No disclosed funding or revenue data raises questions about financial health
  • Heavy reliance on microarray tech, which faces competition from newer sequencing methods

Key Information

Headquarters
Northbrook, Illinois

Frequently Asked Questions

What does GenUs BioSystems specialize in?

GenUs BioSystems provides end-to-end gene expression analysis using microarray technology. Their services include RNA isolation, amplification, microarray processing, and bioinformatics. They specialize in handling ultra-low RNA quantities down to 100 picograms and participated in FDA-led quality control initiatives for reproducible results.

How fast can GenUs BioSystems process microarray samples?

The company claims turnaround times as fast as 5 days for time-sensitive research projects. This includes complete processing from sample preparation to data analysis. Their rapid service is complemented by unlimited post-experiment consulting, making them suitable for urgent academic or pharmaceutical research timelines.

What types of organizations use GenUs BioSystems' services?

Their primary clients include academic genomics labs, pharmaceutical companies developing gene therapies, biotech firms needing precise expression data, and clinical research organizations outsourcing microarray work. The company focuses on scientist-to-scientist collaboration for complex gene expression analysis projects across these sectors.

Is GenUs BioSystems involved in regulatory standards development?

Yes, they participated in the FDA-led MicroArray Quality Control (MAQC) Consortium, demonstrating adherence to regulatory standards. This involvement suggests their methods produce reproducible results that meet pharmaceutical and clinical research requirements for reliable gene expression data analysis.

What are the limitations of GenUs BioSystems' approach?

The company relies heavily on microarray technology, which faces competition from newer sequencing methods. Their online presence appears outdated with no significant updates since early 2020s, and they haven't disclosed recent funding or revenue data, raising questions about current operational scale.

Can GenUs BioSystems work with very small RNA samples?

Yes, they specialize in analyzing ultra-low quantity samples, handling RNA amounts as small as 100 picograms. This capability benefits researchers with limited biological material, such as rare clinical samples or precious laboratory specimens requiring precise gene expression profiling.

Sources

  1. www.genusbiosystems.com — Company services, product offerings, and self-reported capabilities
  2. www.linkedin.com — IP leadership and legal expertise
  3. www.linkedin.com — Product and portfolio leadership in genomics
  4. www.sec.gov — Regulatory filings context (though no direct GenUs data found)